Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLTREG-T1D plus rituximab in pediatric presymptomatic type 1 diabetes
2023-505226-33-00Phase 2Authorised
- Sponsor
- PolTREG
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Regulatory T Cells (Tregs) → Immune Effector Cells → Other Cell Types → Cell Therapies, Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing POLTREG-T1D + rituximab with Control: placebo (2 arms). Primary endpoints: Stage status at end of trial and Adverse events. Planned start Jan 2025; status: authorised.
02
Drugs
PTG-007rituximab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2023-505226-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505226-33-00.